Revive Therapeutics Enters into Clinical Trial Agreement to Evaluate Psilocybin for the Treatment of Methamphetamine Use Disorder

TORONTO, Sept. 02, 2020 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or…

Revive Therapeutics Announces IRB Approval for Phase 3 Clinical Trial Protocol for Bucillamine in COVID-19

TORONTO, Aug. 31, 2020 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or…

Revive Therapeutics Announces Submission of IRB Approval for Phase 3 Clinical Trial Protocol for Bucillamine in COVID-19

Revive to also explore FDA Expanded Access Program (Compassionate Use) for Bucillamine in COVID-19

Revive Therapeutics to Expand Phase 3 Clinical Trial for Bucillamine in COVID-19 in Asia-Pacific and Canada

TORONTO, Aug. 19, 2020 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or…

Revive Therapeutics Signs MOU with Attwill Medical Solutions for Phase 3 Clinical Trial for Bucillamine in COVID-19

TORONTO, Aug. 14, 2020 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or…

Revive Therapeutics Advancing Drug Delivery Technology for Psychedelics

Developed Prototypes of Orally Dissolvable Thin Film For Psilocybin TORONTO, Aug. 11,…

Revive Therapeutics Update Following U.S. FDA Approval of Phase 3 Clinical Trial for Bucillamine in COVID-19

TORONTO, Aug. 05, 2020 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or…

Revive Therapeutics Announces U.S. FDA Approval of Confirmatory Phase 3 Clinical Trial for Bucillamine in COVID-19

TORONTO, July 31, 2020 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or…

Revive Therapeutics Announces Submission of Investigational New Drug Application (IND) with U.S. FDA for Phase 3 Confirmatory Study for Bucillamine in COVID-19

TORONTO, June 30, 2020 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or…

Revive Therapeutics Expands Research Partnership for Novel Formulation Development and Clinical Research of Psilocybin with the University of Wisconsin-Madison

TORONTO, June 12, 2020 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or…